|
|
Reference
|
|
|
André, P., Novy, J., Decosterd, L.A., Buclin, T., Rothuizen, L.E. (2015) Therapeutic drug monitoring of antiepileptic drugs in the 21st century. Epileptologie, 32, 78-84
|
|
 
|
Babaei, A., Eslamai, M.H. (2007) Evaluation of therapeutic drug level monitoring of phenobarbital, phenytoin and carbamazepine in Iranian epileptic patients. Int. Journal of Clinical Pharmacology and Therapeutics, 45(02), 121-125
|
|
|
Baldelli, S., Cattaneo, D., Giodini, L., Baietto, L., di Perri, G., D'avolio, A., Clementi, E.D. (2015) Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. Clinical Chemistry and Laboratory Medicine (CCLM), 53(3), 435-444
|
|
|
Battino, D., Croci, D., Granata, T., Estienne, M., Pisani, F., Avanzini, G. (1997) Lamotrigine plasma concentrations in children and adults: Influence of age and associated therapy. Ther Drug Monit, 19(6), 620-627
|
|
|
Beghi, E., Trevisan, D., Tognoni, G. (1992) Use of plasma levels for antiepileptic drug monitoring in clinical practice: Gruppo Collaborativo per lo Studio dell'Epilessia. Ital J Neurol Sci, 13(1), 59-65
|
|
|
Benetello, P., Furlanut, M., Baraldo, M., Tonon, A., Furlanut, M. (2002) Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures. European Neurology, 48(4), 200-203
|
|
|
Bentué-Ferrer, D., Tribut, O., Verdier, M.C. (2010) Le groupe suivi théra-peutique pharmacologique de la société française de pharmacologie et de thérapeutique: Therapeutic drug monitoring of lamotrigine. Therapie, 65(1), 39-46
|
|
|
Bentué-Ferrer, D., Tribut, O., Verdier, M.C. (2010) Le groupe suivi thérapeutique pharmacologique de la société française de pharmacologie et de thérapeutique. Therapie, 65(1), 51-55
|
|
|
Bentué-Ferrer, D., Tribut, O., Verdier, M.C. (2010) Le groupe suivi théra-peutique pharmacologique de la société française de pharmacologie et de thérapeutique: Therapeutic drug monitoring of pregabaline. Therapie, 65(1), 47-49
|
|
|
Bentué-Ferrer, D., Tribut, O., Verdier, M.C. (2010) Le groupe suivi thérapeutique pharmacologique de la Société Française de pharmacologie et de thérapeutique: Therapeutic drug monitoring of vigabatrin. Therapie, 65(1), 23-27
|
|
|
Briscoe, S.E., McWhinney, B.C., Lipman, J., Roberts, J.A., Ungerer, J.P.J. (2012) A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. Journal of Chromatography B, 907, 178-184
|
|
|
Charfi, R., Lakhal, M., Klouz, A., Trabelsi, S., Salouage, I. (2015) Therapeutic drug monitoring of valproic acid in children: A prospective study of the effect of the compliance and the economic level on the trough plasmatic concentrations and epileptic seizures. Therapie, 70(5), 415-424
|
|
|
Dupont, S., Biraben, A., Lavernhe, G., Marquet, T., Allaf, B. (2013) Management and monitoring of patients treated with zonisamide: The OZONE study. Epileptic Disorders, 15(3), 278-288
|
|
|
Dwivedi, R., Singh, M., Kaleekal, T., Gupta, Y.K., Tripathi, M. (2016) Concentration of antiepileptic drugs in persons with epilepsy: A comparative study in serum and saliva. International Journal of Neuroscience, 126(11), 972-978
|
|
|
Dwivedi, R., Gupta, Y.K., Singh, M., Joshi, R., Tiwari, P., Kaleekal, T., Tripathi, M. (2015) Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy. Seizure, 25, 187-190
|
|
|
Eadie, M.J. (1997) Indications for plasma drug monitoring in patients with epilepsy: Implications for reducing costs. Pharmacoeconomics, 11(4), 343-349
|
|
|
Ferrari, A.R., Guerrini, R., Gatti, G., Alessandri, M.G., Bonanni, P., Perucca, E. (2003) Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Therapeutic Drug Monitoring, 25(6), 700-708
|
|
|
Franco, V., Marchiselli, R., Fattore, C., Tartara, E., de Sarro, G., Russo, E., Perucca, E. (2016) Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma. Therapeutic Drug Monitoring, 38(6), 744-750
|
|
|
Franco, V., French, J.A., Perucca, E. (2016) Challenges in the clinical development of new antiepileptic drugs. Pharmacological Research, 103, 95-104
|
|
|
French, J.A., Gazzola, D.M. (2011) New generation antiepileptic drugs: What do they offer in terms of improved tolerability and safety?. Therapeutic Advances in Drug Safety, 2(4), 141-158
|
|
|
Fröscher, W., Schier, K.R., Hoffmann, M., Meyer, A., May, T.W., Rambeck, B. (2005) Topiramate: A prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord, 7(3), 237-248
|
|
|
Fröscher, W., Keller, F., Vogt, H., Krämer, G. (2002) Prospective study on concentration-efficacy and concentration-toxicity: Correlations with lamotrigine serum levels. Epileptic Disord, 4(1), 49-56
|
|
|
Glauser, T.A., Pippenger, C.E. (2000) Controversies in blood-level monitoring: Reexamining its role in the treatment of epilepsy. Epilepsia, 41(s8), S6-S15
|
|
|
Goldenberg, M.M. (2010) Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment. Pharm Ther, 35(7), 392-415
|
|
|
Greenberg, R.G., Melloni, C., Wu, H., Gonzalez, D., Ku, L., Hill, K.D. (2016) Therapeutic index estimation of antiepileptic drugs: A systematic literature review approach. Clin Neuropharmacol, 39(5), 232-240
|
|
|
Jacob, S., Nair, A.B. (2016) An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs in R&D, 16(4), 303-316
|
|
|
Jannuzzi, G., Cian, P., Fattore, C., Gatti, G., Bartoli, A., Monaco, F., Perucca, E. (2000) A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia, 41(2), 222-230
|
|
|
Jansen, A.J., Hunfeld, N.G., Bommel, J., Koch, B.C., Gelder, T. (2012) Therapeutic drug monitoring of free fraction valproic acid in patients with hypoalbuminaemia. Neth J Med, 70(7), 329-329
|
|
|
Johannessen, L.C., Beiske, G., Baftiu, A., Burns, M.L., Johannessen, S.I. (2015) Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure, 28, 88-91
|
|
|
Johannessen, S.I., Battino, D., Berry, D.J., Bialer, M., Krämer, G., Tomson, T., Patsalos, P.N. (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Therapeutic Drug Monitoring, 25(3), 347-363
|
|
|
Klein, P., Tyrlikova, I., Brazdil, M., Rektor, I. (2016) Brivaracetam for the treatment of epilepsy. Expert Opinion on Pharmacotherapy, 17(2), 283-295
|
|
|
Krasowski, M.D., Penrod, L.E. (2012) Clinical decision support of therapeutic drug monitoring of phenytoin: Measured versus adjusted phenytoin plasma concentrations. BMC Medical Informatics and Decision Making, 12(1), 7-7
|
|
|
Luszczki, J.J. (2009) Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports, 61(2), 197-216
|
|
|
May, T.W., Boor, R., Rambeck, B., Jürgens, U., Korn-Merker, E., Brandt, C. (2011) Serum concentrations of rufinamide in children and adults with epilepsy: The influence of dose, age, and comedication. Therapeutic Drug Monitoring, 33(2), 214-221
|
|
|
Melten, J.W., Wittebrood, A.J., Willems, H.J.J., Faber, G.H., Wemer, J., Faber, D.B. (1985) Comparison of equilibrium dialysis, ultrafiltration, and gel permeation chromatography for the determination of free fractions of phenobarbital and phenytoin. Journal of Pharmaceutical Sciences, 74(6), 692-694
|
|
|
Meneghello, A., Tartaggia, S., Alvau, M.D., Polo, F., Toffoli, G. (2017) Biosensing technologies for therapeutic drug monitoring. Curr Med Chem, Jul 20
|
|
|
Miles, M.V., Tennison, M.B., Greenwood, R.S. (1991) Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Therapeutic Drug Monitoring, 13(2), 166-171
|
|
|
Milovanović, B., Tomović, D., Janković, S.M., Grubor, I., Nikolić, L., Nikolić, M., Mijajlović, M., Mrvić, S., Divjak, A., Milojević, A., Đoković, J., Prokić, A., Bukonjić, A., Sekulić, M., Matić, V. (2017) Faktori koji utiču na strah od igle kod studenata medicine i farmacije. Acta Facultatis Medicae Naissensis, vol. 34, br. 2, str. 147-158
|
|
|
Mula, M. (2016) Third generation antiepileptic drug monotherapies in adults with epilepsy. Expert Review of Neurotherapeutics, 16(9), 1087-1092
|
|
2
|
Patsalos, P.N., Berry, D.J. (2013) Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Therapeutic Drug Monitoring, 35(1), 4-29
|
|
|
Patsalos, P.N., Berry, D.J., Bourgeois, B.F.D., Cloyd, J.C., Glauser, T.A., Johannessen, S.I., Leppik, I.E., Tomson, T., Perucca, E. (2008) Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 49(7), 1239-1276
|
|
|
Pennell, P.B., Peng, L., Newport, D.J., Ritchie, J.C., Koganti, A., Holley, D.K., Newman, M., Stowe, Z.N. (2008) Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency. Neurology, 70(Issue 22, Part 2), 2130-2136
|
|
|
Perucca, E. (1984) Free level monitoring of antiepileptic drugs clinical usefulness and case studies. Clinical Pharmacokinetics, 9(Supplement 1), 71-78
|
|
|
Pippenger, C.E. (2006) Therapeutic drug monitoring assay development to improve efficacy and safety. Epilepsy Research, 68(1), 60-63
|
|
|
Sanavio, B., Krol, S. (2015) On the slow diffusion of point-of-care systems in therapeutic drug monitoring. Frontiers in Bioengineering and Biotechnology, 3, 20-20
|
|
|
Schmidt, D., Haenel, F. (1984) Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: Individual variation in relation to seizure frequency and type. Neurology, 34(9), 1252-1255
|
|
|
Sharma, S., Joshi, S., Mukherji, S., Bala, K., Tripathi, C.B. (2009) Therapeutic drug monitoring: appropriateness and clinical utility in neuropsychiatry practice. American Journal of Therapeutics, 16(1), 11-16
|
|
|
Stepanova, D., Beran, R.G. (2014) Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Seizure, 23(5), 371-376
|
|
|
Svendsen, T., Brodtkorb, E., Reimers, A., Molden, E., Sætre, E., Johannessen, S.I., Johannessen, L.C. (2017) Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate: A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome. Epilepsy Research, 129, 125-131
|
|
|
Svendsen, T., Brodtkorb, E., Baftiu, A., Burns, M.L., Johannessen, S.I., Johannessen, L.C. (2017) Therapeutic drug monitoring of lacosamide in Norway: Focus on pharmacokinetic variability, efficacy and tolerability. Neurochemical Research, 42(7), 2077-2083
|
|
|
Tribut, O., Bentué-Ferrer, D., Verdier, M.C. (2010) Le groupe suivi théra-peutique pharmacologique de la Société Française de Pharmacologie et de Thérapeutique: Therapeutic drug monitoring of felbamate. Therapie, 65(1), 35-38
|
|
|
Walson, P.D. (1985) Practical problems of therapeutic drug monitoring of anticonvulsants. Brain and Development, 7(2), 116-121
|
|
|
|
|